Real-World Efficacy And Safety Of AzacitidineVenetoclax In Acute Myeloid Leukemia: A Retrospective Single-Center Study
IOSR Journal of Nursing and health Science · 2026-03 · 15 (3) · 01-05
DOI: 10.9790/1959-1503010105 ↗Kurz gefasst
Fachartikel in der Zeitschrift IOSR Journal of Nursing and health Science, 2026-03. Verfasst von Karrat Imane und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with dismal outcome especially in older or comorbid patients not candidate for intensive chemotherapy. The gold standard first line therapy in this population has become the Azacitidine-Venetoclax combination in the wake of the practice changing VIALE-A trial.
Methods
We conducted a retrospective cohort study to evaluate 10 AML patients treated with AzacitidineVenetoclax at the Clinical Hematology Department of Moulay Ismail Military Hospital, Meknes, between January 2021 to May 2025. Efficacy was based on modified IWG response criteria. The Kaplan-Meier method was used for survival analyses. Events were grade according to the CTCAE.
Results
The median age was 68.7 years (range, 60–76). Eight patients (80 %) were treated with the regimen as the first-line therapy. After three cycles, the composite CR rate was 70 %. The median OS and PFS were 21.93 months and 10.3 months, respectively. Grade 3–4 neutropenia was universal (100%), then thrombocytopenia (90%) and bacterial infections (90%).
Conclusion
Our results align with VIALE-A and real-world experiences, and In conclusion, the AzacitidineVenetoclax combination showed encouraging activity and a fair toxicity profile in our cohort. Greater availability of this regimen is still a challenge in our setting.
Zitieren
APA
Imane, K., & Hicham, E. (2026). Real-World Efficacy And Safety Of AzacitidineVenetoclax In Acute Myeloid Leukemia: A Retrospective Single-Center Study. IOSR Journal of Nursing and health Science, 15(3), 01-05. https://doi.org/10.9790/1959-1503010105
Vancouver
Imane K, Hicham E. Real-World Efficacy And Safety Of AzacitidineVenetoclax In Acute Myeloid Leukemia: A Retrospective Single-Center Study. IOSR Journal of Nursing and health Science. 2026;15(3):01-05. doi:10.9790/1959-1503010105
BibTeX
@article{Imane2026,
author = {Imane, Karrat and Hicham, Eddou},
title = {Real-World Efficacy And Safety Of AzacitidineVenetoclax In Acute Myeloid Leukemia: A Retrospective Single-Center Study},
journal = {IOSR Journal of Nursing and health Science},
year = {2026},
volume = {15},
number = {3},
pages = {01--05},
doi = {10.9790/1959-1503010105}
}
EUVIMED